BlueRock Therapeutics, a Bayer subsidiary, is teaming up with Opsis Therapeutics and Fujifilm Cellular Dynamics in an R&D pact focused on developing stem cell therapies for eye diseases. BlueRock is paying its new partners $30 million up front to kick off the alliance.

Source: Bayer’s BlueRock Therapeutics widens cell therapy scope to the eye under new pact

Leave a Reply

Your email address will not be published.